Yujiro Naito

980 total citations
29 papers, 386 citations indexed

About

Yujiro Naito is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Yujiro Naito has authored 29 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Immunology. Recurrent topics in Yujiro Naito's work include Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Research Studies (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Yujiro Naito is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Research Studies (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Yujiro Naito collaborates with scholars based in Japan, United States and United Kingdom. Yujiro Naito's co-authors include Shohei Koyama, Atsushi Kumanogoh, Austen Riggs, Mingrui Zhu, Esra A. Akbay, Kwok‐Kin Wong, Yvonne Y. Li, Min Wu, Wei Huang and Peter S. Hammerman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Scientific Reports.

In The Last Decade

Yujiro Naito

27 papers receiving 380 citations

Peers

Countries citing papers authored by Yujiro Naito

Since Specialization

Citations

This map shows the geographic impact of Yujiro Naito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yujiro Naito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yujiro Naito more than expected).

Fields of papers citing papers by Yujiro Naito

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yujiro Naito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yujiro Naito. The network helps show where Yujiro Naito may publish in the future.

Co-authorship network of co-authors of Yujiro Naito

This figure shows the co-authorship network connecting the top 25 collaborators of Yujiro Naito. A scholar is included among the top collaborators of Yujiro Naito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yujiro Naito. Yujiro Naito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report 2025 ·Allergy Asthma and Clinical Immunology ·(unknown), Shimpei Miyamoto, (unknown), Atsushi Yanagisawa, (unknown), Kensuke Kanaoka, Hanako Yoshimura, Tatsunori Jo, (unknown), Yujiro Naito, Takayuki Shiroyama, Satoshi Tetsumoto, Haruhiko Hirata, Yoshito Takeda, Atsushi Kumanogoh	0
2	Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugates 2025 ·EBioMedicine ·Yuichi Adachi, Kotaro Miyake, (unknown), S. Satoh, Kentaro Masuhiro, Ryuya Edahiro, Yuya Shirai, Maiko Naito, Yujiro Naito, Takayuki Shiroyama, Shohei Koyama, Haruhiko Hirata, Kota Iwahori, Izumi Nagatomo, Yoshito Takeda, Atsushi Kumanogoh	0
3	Cancer-associated SNRPD3 mutation confers resistance to hypoxia, which is attenuated by DRP1 inhibition 2024 ·Biochemical and Biophysical Research Communications ·S. Satoh, Kotaro Miyake, Yuichi Adachi, Kentaro Masuhiro, (unknown), Yujiro Naito, Takayuki Shiroyama, Shohei Koyama, Yuta Yamaguchi, (unknown), Hyota Takamatsu, Daisuke Okuzaki, Izumi Nagatomo, Yoshito Takeda, Atsushi Kumanogoh	1
4	Balloon Dilatation for Bronchoscope Delivery in a Swine Model: A Novel Technique for Ultra-Peripheral Lung Field Access and Accurate Biopsy 2024 ·Respiration ·Kotaro Miyake, Takayuki Shiroyama, (unknown), Yuichi Adachi, (unknown), Yuko Abe, (unknown), Kentaro Masuhiro, Yujiro Naito, Haruhiko Hirata, Izumi Nagatomo, Yoshito Takeda, Atsushi Kumanogoh	1
5	Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs 2023 ·Scientific Reports ·Mari Tone, Kota Iwahori, Takayuki Shiroyama, (unknown), Yujiro Naito, Kiyoharu Fukushima, Kotaro Miyake, Shohei Koyama, Haruhiko Hirata, Izumi Nagatomo, Hisashi Wada, Yoshito Takeda, Atsushi Kumanogoh	4
6	Semaphorin 6D–expressing mesenchymal cells regulate IL-10 production by ILC2s in the lung 2022 ·Life Science Alliance ·Maiko Naito, Yoshimitsu Nakanishi, Yasutaka Motomura, Hyota Takamatsu, Shohei Koyama, Masayuki Nishide, Yujiro Naito, (unknown), Yumiko Mizuno, Yuta Yamaguchi, Satoshi Nojima, Daisuke Okuzaki, Atsushi Kumanogoh	8
7	Leucine-rich a-2 glycoprotein as a potential biomarker of idiopathic multicentric Castleman disease with pulmonary involvement: a single-center case-control study from Japan 2022 ·Journal of Thoracic Disease ·(unknown), Yoshito Takeda, Haruhiko Hirata, Yuya Shirai, Takayoshi Morita, (unknown), Yujiro Naito, Kentaro Masuhiro, Takayuki Shiroyama, Kotaro Miyake, Tetsuji Naka, Atsushi Kumanogoh	2
8	Respiratory Impedance is Associated with Ventilation and Diffusing Capacity in Patients with Idiopathic Pulmonary Fibrosis Combined with Emphysema 2022 ·International Journal of COPD ·Yuji Yamamoto, Haruhiko Hirata, Takayuki Shiroyama, Tomoki Kuge, Kinnosuke Matsumoto, (unknown), Makoto Yamamoto, Yujiro Naito, Yasuhiko Suga, Kiyoharu Fukushima, Kotaro Miyake, Shohei Koyama, Kota Iwahori, Izumi Nagatomo, Yoshito Takeda, Atsushi Kumanogoh	3
9	Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer 2022 ·Scientific Reports ·Yoshimi Noda, Takayuki Shiroyama, Kentaro Masuhiro, Saori Amiya, Takatoshi Enomoto, Yuichi Adachi, Reina Hara, Takayuki Niitsu, Yujiro Naito, Kotaro Miyake, Shohei Koyama, Haruhiko Hirata, Izumi Nagatomo, Yoshito Takeda, Atsushi Kumanogoh	10
10	A case of synchronous triple autoimmune disorders secondary to thymoma: Pure red cell aplasia, Good's syndrome, and thymoma-associated multi-organ autoimmunity 2022 ·Respiratory Medicine Case Reports ·(unknown), Kinnosuke Matsumoto, (unknown), Haruhiko Hirata, Takayuki Shiroyama, Kotaro Miyake, Y. Yamamoto, Tomoki Kuge, (unknown), Yujiro Naito, Yasuhiko Suga, Kiyoharu Fukushima, Shohei Koyama, Kota Iwahori, Izumi Nagatomo, Yoshito Takeda, Atsushi Kumanogoh	2
11	Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies 2022 ·Translational Lung Cancer Research ·Kinnosuke Matsumoto, Takayuki Shiroyama, Tomoki Kuge, Kotaro Miyake, Yuji Yamamoto, (unknown), Makoto Yamamoto, Yujiro Naito, Yasuhiko Suga, Kiyoharu Fukushima, Shohei Koyama, Kota Iwahori, Haruhiko Hirata, Izumi Nagatomo, Yoshito Takeda, Atsushi Kumanogoh	5
12	Management of severe hypertension due to lenvatinib in patients with advanced thymic carcinoma 2022 ·Medicine ·Kinnosuke Matsumoto, Takayuki Shiroyama, Kotaro Miyake, Yuji Yamamoto, Tomoki Kuge, (unknown), Makoto Yamamoto, Yujiro Naito, Yasuhiko Suga, Kiyoharu Fukushima, Shohei Koyama, Kota Iwahori, Haruhiko Hirata, Izumi Nagatomo, Yoshito Takeda, Atsushi Kumanogoh	4
13	Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients 2022 ·Scientific Reports ·Kota Iwahori, Takeshi Uenami, Yukihiro Yano, Toshihiko Ueda, Mari Tone, Yujiro Naito, Yasuhiko Suga, Kiyoharu Fukushima, Takayuki Shiroyama, Kotaro Miyake, Shohei Koyama, Haruhiko Hirata, Izumi Nagatomo, Hiroshi Kida, Masahide Mori, Yoshito Takeda, Atsushi Kumanogoh, Hisashi Wada	9
14	Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis 2021 ·Cancer Research ·Mingrui Zhu, Yi Huang, (unknown), Luc Girard, Rahul K. Kollipara, (unknown), Yujiro Naito, Trisha K. Savage, Kenneth E. Huffman, Shohei Koyama, Atsushi Kumanogoh, John D. Minna, Jane E. Johnson, Esra A. Akbay	56
15	Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis 2021 ·Lung Cancer ·Kinnosuke Matsumoto, Takayuki Shiroyama, Tomoki Kuge, Kotaro Miyake, Yuji Yamamoto, (unknown), Makoto Yamamoto, Yujiro Naito, Yasuhiko Suga, Kiyoharu Fukushima, Shohei Koyama, Kota Iwahori, Haruhiko Hirata, Izumi Nagatomo, Yoshito Takeda, Atsushi Kumanogoh	11
16	Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion 2021 ·Investigational New Drugs ·Motohiro Tamiya, Akihiro Tamiya, Hidekazu Suzuki, Yoshihiko Taniguchi, (unknown), (unknown), Keiko Nakao, Naoko Takeuchi, Yoshinobu Matsuda, Yujiro Naito, Takayuki Shiroyama, Norio Okamoto, Kyoichi Okishio, Toru Kumagai, Shinji Atagi, Fumio Imamura, Tomonori Hirashima	9
17	A Microfluidic Platform for Single Cell Fluorometric Granzyme B Profiling 2019 ·Theranostics ·(unknown), (unknown), Shohei Koyama, Hiroyuki Yoshikawa, Jeong Hoon Park, Yujiro Naito, Atsushi Kumanogoh, Eiichi Tamiya, Hyota Takamatsu, Masato Saito	19
18	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity 2019 ·Journal for ImmunoTherapy of Cancer ·Juan J. Miret, Paul T. Kirschmeier, Shohei Koyama, Mingrui Zhu, Yvonne Y. Li, Yujiro Naito, Min Wu, Venkat S. Malladi, Wei Huang, William H. Walker, Sangeetha Palakurthi, Glenn Dranoff, Peter S. Hammerman, Chad V. Pecot, Kwok‐Kin Wong, Esra A. Akbay	108
19	Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations 2017 ·Investigational New Drugs ·Motohiro Tamiya, Akihiro Tamiya, Takayuki Shiroyama, (unknown), Yujiro Naito, Naoki Omachi, (unknown), Naoko Morishita, Hidekazu Suzuki, Norio Okamoto, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi, Tomonori Hirashima	3
20	Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation 2017 ·Medicine ·Taro Koba, Takashi Kijima, Takayuki Takimoto, Haruhiko Hirata, Yujiro Naito, Masanari Hamaguchi, Tomoyuki Otsuka, Muneyoshi Kuroyama, Izumi Nagatomo, Yoshito Takeda, Hiroshi Kida, Atsushi Kumanogoh	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact